Antibiofilm activity and synergistic inhibition of Staphylococcus aureus biofilms by bactericidal protein P128 in combination with antibiotics

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 12, 2016, Pages 7280-7289

  Nair, Sandhya ^a   Desai, Srividya ^a   Poonacha, Nethravathi ^a   Vipra, Aradhana ^a   Sharma, Umender ^a  

^a Gangagen Biotechnologies Pvt Ltd   (India)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; BACTERICIDAL PROTEIN P128; CIPROFLOXACIN; DAPTOMYCIN; GENTAMICIN; LINEZOLID; PROTEIN ANTIBODY; UNCLASSIFIED DRUG; VANCOMYCIN; ANTIINFECTIVE AGENT; DRUG COMBINATION; HYBRID PROTEIN; P128 ANTISTAPHYLOCOCCAL CHIMERIC PROTEIN;

ARTICLE; ASSAY; BACTERICIDAL ACTIVITY; BACTERIUM ISOLATE; BIOFILM; CATHETER; COLONY FORMING UNIT; COLORIMETRY; CONTROLLED STUDY; MICROTITER PLATE ASSAY; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; WOUND INFECTION; DRUG COMBINATION; DRUG EFFECTS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST; MULTIDRUG RESISTANCE;

ANTI-BACTERIAL AGENTS; BIOFILMS; CIPROFLOXACIN; DAPTOMYCIN; DRUG COMBINATIONS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENTAMICINS; LINEZOLID; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; RECOMBINANT FUSION PROTEINS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 84996565674     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01118-16     Document Type: Article

References (39)

1. Yayan J, Ghebremedhin B, Rasche K. 2015. No outbreak of vancomycin and linezolid resistance in staphylococcal pneumonia over a 10-year period. PLoS One 10:e0138895. http://dx.doi.org/10.1371/journal.pone.0138895.
2. Kelley PG, Gao W, Ward PB, Howden BP. 2011. Daptomycin nonsusceptibility in vancomycin-intermediate Staphylococcus aureus (VISA) and heterogeneous-VISA (hVISA): implications for therapy after vancomycin treatment failure. J Antimicrob Chemother 66:1057-1060. http://dx.doi.org/10.1093/jac/dkr066.
3. Gu B, Kelesidis T, Tsiodras S, Hindler J, Humphries RM. 2013. The emerging problem of linezolid-resistant Staphylococcus. J Antimicrob Chemother 68:4-11. http://dx.doi.org/10.1093/jac/dks354.
4. Otto M. 2008. Staphylococcal biofilms. Curr Top Microbiol Immunol 322:207-228.
5. Thwaites GE, Edgeworth JD, Gkrania-Klotsas E, Kirby A, Tilley R, Török ME, Walker S, Wertheim HF, Wilson P, Llewelyn MJ, UK Clinical Infection Research Group. 2011. Clinical management of Staphylococcus aureus bacteraemia. Lancet Infect Dis 11:208-222. http://dx.doi.org/10.1016/S1473-3099(10)70285-1.
6. Keren I, Kaldalu N, Spoering A, Wang Y, Lewis K. 2004. Persister cells and tolerance to antimicrobials. FEMS Microbiol Lett 230:13-18. http://dx.doi.org/10.1016/S0378-1097(03)00856-5.
7. Lewis K. 2008. Multidrug tolerance of biofilms and persister cells. Curr Top Microbiol Immunol 322:107-131.
8. Nguyen D, Joshi-Datar A, Lepine F, Bauerle E, Olakanmi O, Beer K, McKay G, Siehnel R, Schafhauser J, Wang Y, Britigan BE, Singh PK. 2011. Active starvation responses mediate antibiotic tolerance in biofilms and nutrient-limited bacteria. Science 334:982-986. http://dx.doi.org/10.1126/science.1211037.
9. Rogers GB, Carroll MP, Bruce KD. 2012. Enhancing the utility of existing antibiotics by targeting bacterial behaviour? Br J Pharmacol 165:845-857. http://dx.doi.org/10.1111/j.1476-5381.2011.01643.x.
10. Chung PY, Toh YS. 2014. Anti-biofilm agents: recent breakthrough against multi-drug resistant Staphylococcus aureus. Pathog Dis 70:231-239. http://dx.doi.org/10.1111/2049-632X.12141.
11. Parasion S, Kwiatek M, Gryko R, Mizak L, Malm A. 2014. Bacteriophages as an alternative strategy for fighting biofilm development. Pol J Microbiol 63:137-145.
12. Seth AK, Geringer MR, Nguyen KT, Agnew SP, Dumanian Z, Galiano RD, Leung KP, Mustoe TA, Hong SJ. 2013. Bacteriophage therapy for Staphylococcus aureus biofilm-infected wounds: a new approach to chronic wound care. Plast Reconstr Surg 131:225-234. http://dx.doi.org/10.1097/PRS.0b013e31827e47cd.
13. Loeffler JM, Nelson D, Fischetti VA. 2001. Rapid killing of Streptococcus pneumoniae with a bacteriophage cell wall hydrolase. Science 294:2170-2172. http://dx.doi.org/10.1126/science.1066869.
14. Paul VD, Rajagopalan SS, Sundarrajan S, George SE, Asrani JY, Pillai R, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S. 2011. A novel bacteriophage tail-associated muralytic enzyme (TAME) from phage K and its development into a potent antistaphylococcal protein. BMC Microbiol 11:226. http://dx.doi.org/10.1186/1471-2180-11-226.
15. Schuch R, Lee HM, Schneider BC, Sauve KL, Law C, Khan BK, Rotolo JA, Horiuchi Y, Couto DE, Raz A, Fischetti VA, Huang DB, Nowinski RC, Wittekind M. 2014. Combination therapy with lysin CF-301 and antibiotic is superior to antibiotic alone for treating methicillin-resistant Staphylococcus aureus-induced murine bacteremia. J Infect Dis 209:1469-1478. http://dx.doi.org/10.1093/infdis/jit637.
16. Wu JA, Kusuma C, Mond JJ, Kokai-Kun JF. 2003. Lysostaphin as a potential therapeutic agent for staphylococcal biofilm eradication. Antimicrob Agents Chemother 47:3407-3414. http://dx.doi.org/10.1128/AAC.47.11.3407-3414.2003.
17. Pastagia M, Schuch R, Fischetti VA, Huang DB. 2013. Lysins: the arrival of pathogen-directed anti-infectives. J Med Microbiol 62:1506-1516. http://dx.doi.org/10.1099/jmm.0.061028-0.
18. Roach DR, Donovan DM. 2015. Antimicrobial bacteriophage-derived proteins and therapeutic applications. Bacteriophage 5:e1062590. http://dx.doi.org/10.1080/21597081.2015.1062590.
19. Vipra AA, Desai SN, Roy P, Patil R, Raj JM, Narasimhaswamy N, Paul VD, Chikkamadaiah R, Sriram B. 2012. Antistaphylococcal activity of bacteriophage derived chimeric protein P128. BMC Microbiol 12:41. http://dx.doi.org/10.1186/1471-2180-12-41.
20. Drilling AJ, Cooksley C, Chan C, Wormald PJ, Vreugde S. 2016. Fighting sinus-derived Staphylococcus aureus biofilms in vitro with a bacteriophage-derived muralytic enzyme. Int Forum Allergy Rhinol 6:349-355. http://dx.doi.org/10.1002/alr.21680.
21. Sundarrajan S, Raghupatil J, Vipra A, Narasimhaswamy N, Saravanan S, Appaiah C, Poonacha N, Desai S, Nair S, Bhatt RN, Roy P, Chikkamadaiah R, Durgaiah M, Sriram B, Padmanabhan S, Sharma U. 2014. Bacteriophage-derived CHAP domain protein, P128, kills Staphylococcus cells by cleaving interpeptide cross-bridge of peptidoglycan. Microbiology 160:2157-2169. http://dx.doi.org/10.1099/mic.0.079111-0.
22. George SE, Chikkamadaiah R, Durgaiah M, Joshi AA, Thankappan UP, Madhusudhana SN, Sriram B. 2012. Biochemical characterization and evaluation of cytotoxicity of antistaphylococcal chimeric protein P128. BMC Res Notes 5:280. http://dx.doi.org/10.1186/1756-0500-5-280.
23. Sun Y, Dowd SE, Smith E, Rhoads DD, Wolcott RD. 2008. In vitro multispecies Lubbock chronic wound biofilm model. Wound Repair Regen 16:805-813. http://dx.doi.org/10.1111/j.1524-475X.2008.00434.x.
24. Clinical and Laboratory Standards Institute. 2012. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard. CLSI document M07-A9.9. CLSI, Wayne, PA.
25. Lu X, Yang X, Li X, Lu Y, Ren Z, Zhao L, Hu X, Jiang J, You X. 2013. In vitro activity of sodium new houttuyfonate alone and in combination with oxacillin or netilmicin against methicillin-resistant Staphylococcus aureus. PLoS One 8:e68053. http://dx.doi.org/10.1371/journal.pone.0068053.
26. Burmølle M, Thomsen TR, Fazli M, Dige I, Christensen L, Homøe P, Tvede M, Nyvad B, Tolker-Nielsen T, Givskov M, Moser C, Kirketerp-Møller K, Johansen HK, Høiby N, Jensen PØ, Sørensen SJ, Bjarnsholt T. 2010. Biofilms in chronic infections - a matter of opportunity - monospecies biofilms in multispecies infections. FEMS Immunol Med Microbiol 59:324-336. http://dx.doi.org/10.1111/j.1574-695X.2010.00714.x.
27. Wolcott R, Costerton JW, Raoult D, Cutler SJ. 2013. The polymicrobial nature of biofilm infection. Clin Microbiol Infect 19:107-112. http://dx.doi.org/10.1111/j.1469-0691.2012.04001.x.
28. Dowd SE, Sun Y, Smith E, Kennedy JP, Jones CE, Wolcott R. 2009. Effects of biofilm treatments on the multi-species Lubbock chronic wound biofilm model. J Wound Care 18:508, 510-512.
29. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322. http://dx.doi.org/10.1126/science.284.5418.1318.
30. Archer NK, Mazaitis MJ, Costerton JW, Leid JG, Powers ME, Shirtliff ME. 2011. Staphylococcus aureus biofilms: properties, regulation, and roles in human disease. Virulence 2:445-459. http://dx.doi.org/10.4161/viru.2.5.17724.
31. Donlan RM, Costerton JW. 2002. Biofilms: survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15:167-193. http://dx.doi.org/10.1128/CMR.15.2.167-193.2002.
32. Parsek MR, Singh PK. 2003. Bacterial biofilms: an emerging link to disease pathogenesis. Annu Rev Microbiol 57:677-701. http://dx.doi.org/10.1146/annurev.micro.57.030502.090720.
33. Stewart PS. 2015. Antimicrobial tolerance in biofilms. Microbiol Spectr 3:3. http://dx.doi.org/10.1128/microbiolspec.MB-0010-2014.
34. Fux CA, Costerton JW, Stewart PS, Stoodley P. 2005. Survival strategies of infectious biofilms. Trends Microbiol 13:34-40. http://dx.doi.org/10.1016/j.tim.2004.11.010.
35. McCarthy H, Rudkin JK, Black NS, Gallagher L, O'Neill E, O'Gara JP. 2015. Methicillin resistance and the biofilm phenotype in Staphylococcus aureus. Front Cell Infect Microbiol 5:1. http://dx.doi.org/10.3389/fcimb.2015.00001.
36. Kiri N, Archer G, Climo MW. 2002. Combinations of lysostaphin with beta-lactams are synergistic against oxacillin-resistant Staphylococcus epidermidis. Antimicrob Agents Chemother 46:2017-2020. http://dx.doi.org/10.1128/AAC.46.6.2017-2020.2002.
37. Daniel A, Euler C, Collin M, Chahales P, Gorelick KJ, Fischetti VA. 2010. Synergism between a novel chimeric lysin and oxacillin protects against infection by methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 54:1603-1612. http://dx.doi.org/10.1128/AAC.01625-09.
38. Fish R, Kutter E, Wheat G, Blasdel B, Kutateladze M, Kuhl S. 2016. Bacteriophage treatment of intransigent diabetic toe ulcers: a case series. J Wound Care 7:S27-S33. http://dx.doi.org/10.12968/jowc.2016.25.7.S27.
39. Zhang L, Li D, Li X, Hu L, Cheng M, Xia F, Gong P, Wang B, Ge J, Zhang H, Cai R, Wang Y, Sun C, Feng X, Lei L, Han W, Gu J. 2016. LysGH15 kills Staphylococcus aureus without being affected by the humoral immune response or inducing inflammation. Sci Rep 6:29344. http://dx.doi.org/10.1038/srep29344.